![](/images/graphics-bg.png)
Altered Expression of Long Noncoding and Messenger RNAs in Diabetic Nephropathy following Treatment with Rosiglitazone
Joint Authors
Zhang, Liwen
Zhou, Ying
Zhou, Fangfang
Yu, Xialian
Liu, Jian
Liu, Yunzi
Zhu, Yufei
Wang, Weiming
Chen, Nan
Source
Issue
Vol. 2020, Issue 2020 (31 Dec. 2020), pp.1-17, 17 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2020-01-14
Country of Publication
Egypt
No. of Pages
17
Main Subjects
Abstract EN
Diabetic nephropathy (DN) is characterized by metabolic disorder and inflammation.
However, the regulatory effects that long noncoding RNAs (lncRNAs) have on the pathogenesis of DN and on the efficacy of rosiglitazone treatment have yet to be clearly defined.
Herein, we performed unbiased RNA sequencing to characterize the transcriptomic profiles in db/db diabetic mouse model with or without rosiglitazone treatment that served to improve the phenotypes of DN.
Moreover, RNA-seq profiling revealed that the development of DN caused an upregulation in the expression of 1176 mRNAs and a downregulation in the expression of 1010 mRNAs compared to controls, with the expression of 251 mRNAs being returned to normal following treatment with rosiglitazone.
Further, 88 upregulated and 68 downregulated lncRNAs were identified in db/db mice compared to controls, 10 of which had their normal expression restored following treatment with rosiglitazone.
Bioinformatic analysis revealed that the primary pathways involved in the pathogenesis of DN, and subsequently in the therapeutic effects of PPARγ, are related to inflammatory and metabolic processes.
From bioinformatics analysis, lncRNA-AI838599 emerged as a novel molecular mechanism for rosiglitazone treatment in DN through TNFα-NFκb pathway.
These findings may indicate a new molecular regulatory approach for the development of DN therapeutic agents.
American Psychological Association (APA)
Zhang, Liwen& Zhou, Ying& Zhou, Fangfang& Yu, Xialian& Liu, Jian& Liu, Yunzi…[et al.]. 2020. Altered Expression of Long Noncoding and Messenger RNAs in Diabetic Nephropathy following Treatment with Rosiglitazone. BioMed Research International،Vol. 2020, no. 2020, pp.1-17.
https://search.emarefa.net/detail/BIM-1131593
Modern Language Association (MLA)
Zhang, Liwen…[et al.]. Altered Expression of Long Noncoding and Messenger RNAs in Diabetic Nephropathy following Treatment with Rosiglitazone. BioMed Research International No. 2020 (2020), pp.1-17.
https://search.emarefa.net/detail/BIM-1131593
American Medical Association (AMA)
Zhang, Liwen& Zhou, Ying& Zhou, Fangfang& Yu, Xialian& Liu, Jian& Liu, Yunzi…[et al.]. Altered Expression of Long Noncoding and Messenger RNAs in Diabetic Nephropathy following Treatment with Rosiglitazone. BioMed Research International. 2020. Vol. 2020, no. 2020, pp.1-17.
https://search.emarefa.net/detail/BIM-1131593
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-1131593